Noopur Raje, MD, discusses the potential utility of belantamab mafodotin in multiple myeloma.
Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses the potential utility of belantamab mafodotin in multiple myeloma.
In January 2020, the FDA granted a priority review designation to a biologics license application (BLA) for belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who received prior therapy with an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
The agent demonstrated a 31% overall response rate in this patient population in the phase II DREAMM-2 study. Data from the trial served as the basis for the BLA submission.
Pending its approval, the BCMA-targeted agent will be offered as an accessible off-the-shelf antibody-drug conjugate, explains Raje.
With the exception of ocular toxicities that may occur with the agent, belantamab mafodotin appears to be well tolerated. Given the drug’s tolerability, it will likely have clinical utility in combination with other drugs in earlier lines of treatment, concludes Raje.